HKSE · 9606.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Duality Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.31% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Duality Biotherapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$436.60-HK$1.20 (-0.27%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.38% below the high.
HK$49.38-HK$0.54 (-1.08%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.31% below the high.
HK$18.01-HK$0.59 (-3.17%)
Mabwell-b’s quoted price sits in the lower half of its reported 52-week range, 38.28% below the high.
HK$9.79-HK$0.06 (-0.61%)
HBM Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 42.68% below the high.
HK$36.86-HK$0.12 (-0.32%)
Nanjing Leads Biolabs Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 62.19% below the high.
HK$6.30-HK$0.19 (-2.93%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 48.36% below the high.
HK$3.15+HK$0.09 (+2.77%)
Lepu Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.22% below the high.
HK$3.31-HK$0.02 (-0.45%)
BioDlink International Company Limited’s quoted price sits in the lower half of its reported 52-week range, 43.61% below the high.
